Nexalin Technology, Inc. (NXL)

Nexalin Technology will go public soon, but the exact IPO date is still unknown.
Stock Price: $6.00 - $7.00
Current IPO price range

Company Description

Nexalin Technology designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic.

We have developed an easy-to-administer medical device — referred to as Gen-1 – that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy.

This device emits our original waveform at 4 milliamps during treatment and is classified by the FDA as a Class II device. While this device had been cleared by the FDA to treat anxiety and insomnia, we have voluntarily suspended marketing efforts on the Gen-1 device for treatment of anxiety or insomnia until a 510(k) application is approved by the FDA.

We have also already begun designing and developing new advanced waveform technology to be emitted at 15 milliamps through our existing medical device improved with a modern enclosure—referred to as Gen-2— which can penetrate deeper into the brain and the associated structures of mental illness, which we believe will generate enhanced patient response.

Gen-2 is presently being tested in clinical trials, for anxiety, insomnia and depression in the United States and China.

Nexalin Technology, Inc.
Country United States
Founded 2010
Industry Health Care
Sector Biotechnology
Employees 2
CEO Mark White

Contact Details

Address:
1776 Yorktown, Suite 550
Houston, TX 77056
United States
Phone (713) 660-1100
Website nexalin.com

Stock Details

Ticker Symbol NXL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 1527352

Key Executives

Name Position
Mark White President, Chief Executive Officer, Director
David Owens, M.D. Chief Medical Officer, Director
Sam Namiri Chief Financial Officer
Rick Morad Director
Alan Kazden Director
Ben Hu, M.D. Director

Latest SEC Filings

Date Type Title
May 31, 2022 S-1/A General form for registration of securities under the Securities Act of 1933
May 16, 2022 S-1/A General form for registration of securities under the Securities Act of 1933
Apr 27, 2022 S-1/A General form for registration of securities under the Securities Act of 1933
Apr 8, 2022 S-1/A General form for registration of securities under the Securities Act of 1933
Feb 4, 2022 S-1/A General form for registration of securities under the Securities Act of 1933
Jan 28, 2022 S-1/A General form for registration of securities under the Securities Act of 1933
Jan 3, 2022 S-1 General form for registration of securities under the Securities Act of 1933
Dec 7, 2021 DRS/A Draft Registration Statement
Nov 2, 2021 DRS/A Draft Registration Statement
Sep 17, 2021 DRS Draft Registration Statement